Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Novick

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Microbiology Spectrum|August 22, 2022
Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance MonitoringTyler Brady, Tianhui Zhang, Kevin M Tuffy, et al.
The Lancet. Oncology|April 18, 2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trialJean-Yves Blay, Lin Shen, Yoon-Koo Kang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2003
CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humansTimothy K Tippin, Geraldine Hamilton, Linda Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activityGuido Marcucci, Wendy Stock, Guowei Dai, et al.
Molecular Cancer Therapeutics|May 15, 2020
Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive CellsRuoyan Chen, Saravanan Rajan, Michael G Overstreet, et al.
Science Translational Medicine|April 22, 2021
Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trialJohn E Le Lay, Qun Du, Minal B Mehta, et al.
ERJ Open Research|May 25, 2023
Multiomics links global surfactant dysregulation with airflow obstruction and emphysema in COPDVentzislava A Hristova, Alastair Watson, Raghothama Chaerkady, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2022
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305Krista Kinneer, Philipp Wortmann, Zachary A Cooper, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Microbiology Spectrum|August 22, 2022
Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance MonitoringTyler Brady, Tianhui Zhang, Kevin M Tuffy, et al.
The Lancet. Oncology|April 18, 2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trialJean-Yves Blay, Lin Shen, Yoon-Koo Kang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2003
CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humansTimothy K Tippin, Geraldine Hamilton, Linda Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activityGuido Marcucci, Wendy Stock, Guowei Dai, et al.
Molecular Cancer Therapeutics|May 15, 2020
Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive CellsRuoyan Chen, Saravanan Rajan, Michael G Overstreet, et al.
Science Translational Medicine|April 22, 2021
Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trialJohn E Le Lay, Qun Du, Minal B Mehta, et al.
ERJ Open Research|May 25, 2023
Multiomics links global surfactant dysregulation with airflow obstruction and emphysema in COPDVentzislava A Hristova, Alastair Watson, Raghothama Chaerkady, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2022
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305Krista Kinneer, Philipp Wortmann, Zachary A Cooper, et al.
Pageof 4